mechanism of glp 1 agonist action of GLP-1 [25] Understanding GLP-1 receptor agonists and

Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England

Subcutaneous injections deliver the drug directly into the bloodstream, ensuring immediate bioavailability, whereas transdermal patches continuously deliver the drug through the skin

Wegovy (semaglutide) Wegovy is a GLP-1 agonist medication that is approved to: Aid in weight loss for adults and children over 12 years old who have obesity, or in adults who have overweight and have a weight-related health condition (such as high blood pressure, type 2 diabetes , or high cholesterol) Reduce the risk of major cardiovascular events, such as heart attack or stroke, in adults who have cardiovascular disease and have obesity or overweight Wegovy comes in a single-use pen that you inject once per week, either with or without food

Ioffe, S

Diabetologia 42 (7), 856864

Diabetes Obes Metab 23(3):754762 Vilsbll T, Garber AJ (2012) Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide